MedPath

AIDMA: A Psycho-educational Program Designed to Support and Train Carers of Alzheimer's Disease (AD) Patients

Not Applicable
Completed
Conditions
Alzheimer's Disease
Interventions
Behavioral: Controlled diet
Behavioral: Self-hypnotic relaxation
Registration Number
NCT00190372
Lead Sponsor
Assistance Publique - H么pitaux de Paris
Brief Summary

The aim of the project is to demonstrate that a psycho-educational programme designed to support and train carers of Alzheimer's disease (AD) patients induces a significantly higher benefit than anticholinesterase drug treatment alone or associated to memantine treatment. This training programme focuses on the explanation/description of behavioral, cognitive and functional disorders induced by the disease, as well as principles of cognitive and psycho-social stimulation of the patients in daily life.

Detailed Description

Context: Research showing the benefit of a combined approach including specific antidementia drugs and psycho-educational programmes for caregivers in the caring of Alzheimer's disease patients is still lacking. We venture the hypothesis that combined treatment including a specific antidementia drug for the AD patient and a psycho-educational programme for the caregivers has a larger benefit for both the patient and the caregiver on psychological, behavioural, and cognitive parameters.

Main objective: to demonstrate that a psycho-educational programme designed to support and train carers of Alzheimer's disease (AD) patients induces a significantly higher benefit than anticholinesterase drug treatment alone or associated to memantine treatment.

Secondary objective: identify patterns of responders and non-responders (taking into account cognitive, psychological parameters).

Methodology: national multicentric, randomized trial, single blinded, with 2 parallel groups of 120 patients and 120 caregivers trained for a 3 month period with 3 assessments: before, just after and 3 months after the training period. Patients and caregivers are recruited (according to exclusion and inclusion criteria) and followed up in memory centers participating in the trial.

Evaluation criteria:

Primary criteria for the patient: DAD scale (Disability Assessment for Dementia).

Secondary evaluation criteria - for the patient: NPI and ADAS-Cog; for the caregiver: ZARIT scale, Questionnaire of feeling of competency, Montgomery and Asberg Depression Rating Scale (MADRS), Geriatric Depression Scale (GDS).

Statistical analysis by the department of biostatistics and medical computing of the Hospital Cochin will be performed.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
240
Inclusion Criteria

Patients:

  • AD outpatients
  • Stable pharmacological treatment
  • Mini-Mental State Examination (MMSE) [10 -28]
  • Age [60-90]
  • Informed consent

Caregivers:

  • Reliability
  • Motivation
  • Psychological disorder related to patient's disease
  • Need for information or help
  • Informed consent
Read More
Exclusion Criteria

Patients:

  • Other dementia
  • Severe general disease
  • No reliable caregiver

Caregivers:

  • Physical or mental disease incompatible with patient's management
  • Impossibility to participate in the educational program
  • Absence of anxiety-depression
  • Psychotherapy
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
AControlled diet-
ASelf-hypnotic relaxation-
Primary Outcome Measures
NameTimeMethod
DAD scale (Disability Assessment for Dementia)at 6 months
Secondary Outcome Measures
NameTimeMethod
all cause mortalityat one year
score on a depression rating scaleat 6 weeks
cardiovascular mortalityat 6 months
functional statusat 4 weeks
for the patient: NPI and ADAS-Cogduring the study
for the caregiver: ZARIT scale, questionnaire of feeling of competency, Montgomery and Asberg Depression Rating Scale (MADRS), Geriatric Depression Scale (GDS)during the study

Trial Locations

Locations (1)

Assistance Publique-H么pitaux de Paris

馃嚝馃嚪

Paris, Ile de France, France

漏 Copyright 2025. All Rights Reserved by MedPath